[
  {
    "ts": null,
    "headline": "Gilead and Arcus reignite anti-TIGIT interest with Phase II gastric cancer win",
    "summary": "These results could rekindle the anti-TIGIT flame, which was once burning bright in pharma pipelines.",
    "url": "https://finnhub.io/api/news?id=e0b5c9efd3f199ec3771a92490d0a0b8a9b21a8fef2ed6982706ae3995f856d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760442699,
      "headline": "Gilead and Arcus reignite anti-TIGIT interest with Phase II gastric cancer win",
      "id": 137085935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "These results could rekindle the anti-TIGIT flame, which was once burning bright in pharma pipelines.",
      "url": "https://finnhub.io/api/news?id=e0b5c9efd3f199ec3771a92490d0a0b8a9b21a8fef2ed6982706ae3995f856d4"
    }
  }
]